CDK4 and pancreatic adenocarcinoma: Importantly, the combination of MEK and CDK4/6 inhibitors in pancreatic adenocarcinoma induce senescence including the release of SASP factors enriched in pro-angiogenic proteins promoting tumour vascularisation and enhancing drug delivery and efficacy [7].